Your Tuesday Morning Nasdaq Profile (JAN) Update
JAN put together a solid yesterday and it may get better going into Tuesday's opening bell. Here's why...
JAN continues to have multiple triggered technicals in the short, medium, and long term.
Plus, Barchart is still ranking JAN as a "72% BUY" based on overall technical indicators.
Over the past several weeks, JAN has been building momentum from the lower $6.00 range to today's approximate $8.00+ range.
Could this be a major sign of things to come in the near future for JAN?
Remember, Yahoo Finance is reporting JAN to have a low float of approximately 2.38Mn shares.
When it made its initial breakout to its 52-week high back at the end of January, it took place over a 2-day period where it ran from $6.00+ to $31.00+.
That's why you need to watch this profile closely.
If you haven't gotten a chance to read my initial report on JAN below, do so now.
There's little to no time to waste this morning as the opening bell just rang.
Previously, I brought this past champ to your attention back on August 20th, 2020 and watched it rocket approximately $1.50+ on the day I alerted it.
Then, that's when things got interesting.
Fast-forward for a second to the beginning of January, 2021.
On 1/28/21, this profile surged all the way to a 52-week high of $31.83.
From my initial alert back in August, this Nasdaq biotech had climbed over $25 and had delivered a run of approximately 448%.
Now, due to several potential catalysts, this past champ could be gearing up for another potential vertical surge.
For June 21st, there is only one profile to have on your radar:
JanOne Inc. (NASDAQ:JAN)
JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for op-ioid prescriptions to treat disease associated pain that can lead to op-ioid abuse. The company is also exploring solutions for non-addictive pain medications.
Its lead candidate, JAN101, is for potentially treating peripheral artery disease ("PAD"). JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions, and neuropathic pain.
Peripheral Artery Disease (PAD) - What You Need To Know
Peripheral Artery Disease (PAD) impacts about 12 million people in the U.S. alone. If left untreated, it could also lead to a Critical Limb Ischemia: a severe condition with an annual cost of care estimated to be $10Bn. 1 in every 20 adults over age 50, and 1 in every 4 adults over age 70, are also likely to develop PAD.(2)
So far, results from JanOne’s Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of Peripheral Artery Disease.(3)
Nearing Phase 2b trials, JanOne could help address this painful ailment in a potential $5.7Bn PAD market.(1)
And, recent positive Phase 2b trial news could draw serious attention to JAN. Check it out:
Your No. 1 Potential JAN Catalyst
JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
Successfully Completes Initial Batch Production of JAN101, Demonstrating CGMP-scale Production Capabilities
LAS VEGAS, June 8, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and dr-ugs with non-addictive, pain-relieving properties, today announced the successful completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD).
Read the full article here.
Your No. 2 Potential JAN Catalyst
Yahoo Finance is reporting that JAN has a minuscule 2.38Mn shares in its float.
2.38Mn... That's all!
Why is that important? When a st-ock's share structure is such, volatility can potentially take place in the flash of an eye.
With a biotech company, good trial/product news can be a true game-changer and bring serious attention to its st-ock.
Your No. 3 Potential JAN Catalyst
According to Barchart, JAN is currently a "72% BUY" based on overall technical indicators.
Further, Barchart reports that JAN was a "24% SELL" last month. That's a big swing in a short amount of time.
Here are the bullish, triggered technicals the website is reporting (as of close Friday):
Short Term Indicators
- 20 Day Moving Average
- 20 - 50 Day MACD Oscillator
- 20 - 200 Day MACD Oscillator
Medium Term Indicators
- 50 Day Moving Average
- 50 - 150 Day MACD Oscillator
- 50 - 200 Day MACD Oscillator
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - 200 Day MACD Oscillator
Additionally, Barchart's composite "TrendSpotter" technical indicator is triggered as bullish.
Your No. 4 Potential JAN Catalyst
Take a look at JAN's 6-month chart: